Hidden truth: The perils and protection of off-label drug and medical device promotion
Affiliations
- PMID: 21847900
Item in Clipboard
Hidden truth: The perils and protection of off-label drug and medical device promotion
Health Matrix Clevel.
2011.
No abstract available
Similar articles
-
Off-label prescription advertising, the FDA and the First Amendment: a study in the values of commercial speech protection.Am J Law Med. 2011;37(2-3):315-57. doi: 10.1177/009885881103700206. Am J Law Med. 2011. PMID: 21847884 No abstract available.
-
Off-label drug use and promotion: balancing public health goals and commercial speech.Am J Law Med. 2011;37(2-3):225-57. doi: 10.1177/009885881103700202. Am J Law Med. 2011. PMID: 21847880 No abstract available.
-
The future of off-label marketing regulations in the post-Sorrell era.Seton Hall Law Rev. 2013;43(3):1137-63. Seton Hall Law Rev. 2013. PMID: 23802338 No abstract available.
-
Direct-to-consumer prescription drug advertising.Am J Law Med. 1999;25(1):149-67. Am J Law Med. 1999. PMID: 10207573 Review. No abstract available.
-
The complexity of covering off-label use for a multitude of oncology regimens.Am J Manag Care. 2012 Dec;18(5 Spec No.):SP242-7. Am J Manag Care. 2012. PMID: 23301714 Review. No abstract available.